Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Characteristics of Patients With Thymoma in Chulalongkorn Hospital

This study has been completed.
Information provided by:
Chulalongkorn University Identifier:
First received: May 12, 2010
Last updated: November 21, 2010
Last verified: November 2010
The purpose of this study is to study characteristics of patients with thymoma in Chulalongkorn hospital between 2003-2007.

Thymoma Staging
Clinical Presentations
Associated Disorders
Laboratory Findings

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Characteristics of Patients With Thymoma Undergone Thymectomy in Chulalongkorn Hospital Between 2003-2007

Resource links provided by NLM:

Further study details as provided by Chulalongkorn University:

Primary Outcome Measures:
  • Thymoma staging and clinical manifestations [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Associated diseases and laboratory findings Immunological data [ Time Frame: 4 months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Enrollment: 50
Study Start Date: November 2009
Study Completion Date: October 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Patients with thymoma
Normal controls

Detailed Description:
To study characteristics of patients with thymoma undergone thymectomy in Chulalongkorn hospital between 2003-2007 in terms of clinical manifestations, associated diseases, and laboratory findings.

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients with thymoma undergone thymectomy in Chulalongkorn hospital between 2003-2007

Inclusion Criteria:

  • Patients with histocytological proved thymoma undergone thymectomy in Chulalongkorn hospital between 2003-2007

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01123590

Faculty of Medicine, Chulalongkorn University
Bangkok, Thailand, 10330
Sponsors and Collaborators
Chulalongkorn University
Principal Investigator: Jettanong Klaewsongkram, MD Chulalongkorn University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Jettanong Klaewsongkram, Chulalongkorn University Identifier: NCT01123590     History of Changes
Other Study ID Numbers: Chula-ARC 003/09 
Study First Received: May 12, 2010
Last Updated: November 21, 2010
Health Authority: Thailand: Ethical Committee

Keywords provided by Chulalongkorn University:
Autoimmune diseases

Additional relevant MeSH terms:
Thymus Neoplasms
Neoplasms, Complex and Mixed
Neoplasms by Histologic Type
Thoracic Neoplasms
Neoplasms by Site
Lymphatic Diseases processed this record on December 08, 2016